JP2013163674A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013163674A5 JP2013163674A5 JP2013036487A JP2013036487A JP2013163674A5 JP 2013163674 A5 JP2013163674 A5 JP 2013163674A5 JP 2013036487 A JP2013036487 A JP 2013036487A JP 2013036487 A JP2013036487 A JP 2013036487A JP 2013163674 A5 JP2013163674 A5 JP 2013163674A5
- Authority
- JP
- Japan
- Prior art keywords
- endostatin
- cancer
- complex
- polyethylene glycol
- kda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102400001047 Endostatin Human genes 0.000 claims 16
- 108010079505 Endostatins Proteins 0.000 claims 16
- 229920001223 polyethylene glycol Polymers 0.000 claims 12
- 239000002202 Polyethylene glycol Substances 0.000 claims 11
- 239000003405 delayed action preparation Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000002131 composite material Substances 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000010253 intravenous injection Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000008816 organ damage Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- DCESWPKOLYIMNH-UHFFFAOYSA-N 2-(2,5-dioxopyrrolidin-1-yl)propanoic acid Chemical compound OC(=O)C(C)N1C(=O)CCC1=O DCESWPKOLYIMNH-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- SYUXAJSOZXEFPP-UHFFFAOYSA-N glutin Natural products COc1c(O)cc2OC(=CC(=O)c2c1O)c3ccccc3OC4OC(CO)C(O)C(O)C4O SYUXAJSOZXEFPP-UHFFFAOYSA-N 0.000 claims 1
- 229940093915 gynecological organic acid Drugs 0.000 claims 1
- 210000002767 hepatic artery Anatomy 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 229920001477 hydrophilic polymer Polymers 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 239000006174 pH buffer Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910001415 sodium ion Inorganic materials 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610011247.9 | 2006-01-20 | ||
| CNB2006100112479A CN100475270C (zh) | 2006-01-20 | 2006-01-20 | 一种治疗肿瘤的药物及其应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008550619A Division JP5687823B2 (ja) | 2006-01-20 | 2007-01-19 | 癌治療のための医薬品およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013163674A JP2013163674A (ja) | 2013-08-22 |
| JP2013163674A5 true JP2013163674A5 (https=) | 2013-10-03 |
Family
ID=38287273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008550619A Expired - Fee Related JP5687823B2 (ja) | 2006-01-20 | 2007-01-19 | 癌治療のための医薬品およびその使用 |
| JP2013036487A Pending JP2013163674A (ja) | 2006-01-20 | 2013-02-26 | 癌治療のための医薬品およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008550619A Expired - Fee Related JP5687823B2 (ja) | 2006-01-20 | 2007-01-19 | 癌治療のための医薬品およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20100285103A1 (https=) |
| EP (1) | EP1985302B1 (https=) |
| JP (2) | JP5687823B2 (https=) |
| CN (3) | CN100475270C (https=) |
| AU (1) | AU2007207268B2 (https=) |
| CA (1) | CA2637698C (https=) |
| NO (1) | NO20083287L (https=) |
| WO (1) | WO2007082483A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104961831B (zh) | 2007-09-05 | 2020-06-23 | 江苏先声药业有限公司 | 一种修饰的重组人内皮抑素及其应用 |
| CN101396347B (zh) * | 2007-09-27 | 2011-12-14 | 江苏先声药物研究有限公司 | 一种重组人血管内皮抑制素缓释微球的制备方法 |
| CN101265298B (zh) * | 2008-04-30 | 2011-11-09 | 中国药科大学 | 含有非天然氨基酸的内皮抑素突变体及其衍生物 |
| CN101642559B (zh) * | 2008-06-30 | 2012-08-01 | 江苏先声药物研究有限公司 | 含微粉化人血管内皮抑制素的药物组合物 |
| WO2011050311A1 (en) | 2009-10-22 | 2011-04-28 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Use of endostatin peptides for the treatment of fibrosis |
| ES2891564T3 (es) * | 2010-04-01 | 2022-01-28 | Oncorena Ab | Tratamiento mejorado del carcinoma de células renales |
| CN101890155B (zh) * | 2010-05-25 | 2012-07-25 | 江苏先声药物研究有限公司 | 一种药物组合物及其应用 |
| CN102698270B (zh) * | 2011-03-28 | 2016-02-03 | 清华大学 | 一种增强靶细胞摄取治疗剂的方法和药物组合物 |
| JP6336389B2 (ja) * | 2011-09-09 | 2018-06-06 | チンファ ユニヴァーシティＴｓｉｎｇｈｕａ Ｕｎｉｖｅｒｓｉｔｙ | Ａｔｐ結合部位に変異を有するエンドスタチン変異体 |
| CN104926933B (zh) * | 2014-03-19 | 2018-09-07 | 北京仁和天通生物科技有限公司 | Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用 |
| CN104031261B (zh) * | 2014-06-20 | 2017-10-27 | 电子科技大学 | 温敏性共聚物及其水凝胶体系 |
| CN104174015A (zh) * | 2014-08-22 | 2014-12-03 | 广州安辰医药科技有限公司 | 疫苗组合物及其在肿瘤治疗中的用途 |
| CN104515768B (zh) * | 2014-08-29 | 2017-01-25 | 湖南新大陆生物技术有限公司 | 一种肿瘤特异性生长因子检测试剂盒 |
| CN104771603B (zh) * | 2015-04-17 | 2018-05-18 | 张坤镛 | 一种改善唾液酸异常的中药口服药及制备方法 |
| CN106924754B (zh) * | 2015-12-30 | 2021-11-09 | 北京大学 | 聚氨基酸偶联物 |
| CN105646701B (zh) * | 2016-03-29 | 2019-03-05 | 徐根兴 | 不同氨基酸结构的重组人内皮抑素蛋白及其制备方法和应用 |
| CN107865824B (zh) * | 2016-09-28 | 2020-04-03 | 山东先声生物制药有限公司 | 一种稳定的重组人血管内皮抑制素皮下注射组合物 |
| EP3539570B1 (en) * | 2016-11-10 | 2022-04-13 | Beijing Protgen Ltd. | Pegylated endostatin analogue and application thereof |
| CA3103035A1 (en) * | 2017-07-30 | 2019-02-07 | Tsinghua University | Medication for inhibiting dna-pkcs |
| CN109503700A (zh) * | 2017-09-14 | 2019-03-22 | 南京安吉生物科技有限公司 | 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用 |
| CN110870869A (zh) * | 2018-08-31 | 2020-03-10 | 成都夸常奥普医疗科技有限公司 | 包含糖类营养素和常规无效化合物的药物组合物及其应用 |
| WO2022161381A1 (zh) * | 2021-01-26 | 2022-08-04 | 清华大学 | 血管内皮抑制素在治疗和预防冠状病毒相关疾病中的应用 |
| CN113350576A (zh) * | 2021-05-21 | 2021-09-07 | 上海大学 | 快慢交联互补的双网络自愈合可注射水凝胶及其制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911929A (en) | 1986-08-29 | 1990-03-27 | The United States Of America As Represented By The Secretary Of The Navy | Blood substitute comprising liposome-encapsulated hemoglobin |
| AU5858690A (en) * | 1989-06-14 | 1991-01-08 | Cetus Corporation | Polymer/antibiotic conjugate |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| ZA991029B (en) | 1998-02-09 | 1999-09-30 | Rhone Poulenc Rorer Pharma | Composition and methods for treatment of hiv infections. |
| US6689762B1 (en) | 1998-02-09 | 2004-02-10 | Enzon Pharmaceuticals, Inc. | Composition and methods for treatment of HIV infection |
| DK1656952T3 (da) * | 1998-10-16 | 2014-01-20 | Biogen Idec Inc | Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf |
| JP4216480B2 (ja) | 1999-05-17 | 2009-01-28 | コンジュケム バイオテクノロジーズ インコーポレイテッド | ウイルス感染の長期持続性融合ペプチドインヒビター |
| WO2001017568A2 (en) | 1999-09-07 | 2001-03-15 | Conjuchem, Inc. | Bioconjugation in vivo to pulmonary or blood components |
| IL152804A0 (en) * | 2000-05-16 | 2003-06-24 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| WO2002044360A2 (en) * | 2000-11-28 | 2002-06-06 | Phoenix Pharmacologics, Inc. | Modified arginine deiminase |
| EP1401480B1 (en) * | 2001-02-22 | 2012-11-28 | Novartis AG | Viral vectors encoding endostatin in the treatment of ocular neovascularization |
| AU2003244515A1 (en) * | 2002-02-07 | 2003-09-02 | Novozymes Delta Limited | Albumin-fused anti-angiogenesis peptides |
| IL166037A0 (en) * | 2002-07-24 | 2006-01-15 | Hoffmann La Roche | Pegylated t1249 polypeptide |
| NZ538958A (en) * | 2002-08-28 | 2006-09-29 | Novartis Ag | Treating disorders of the retina by increasing the in vivo concentration of endostatin in ocular tissues |
| US7078485B2 (en) * | 2002-12-05 | 2006-07-18 | Yantai Medgenn Ltd. | N-terminal modified recombinant human endostatin and its production |
| JP2006519235A (ja) | 2003-02-26 | 2006-08-24 | インターミューン インコーポレイティッド | ポリエチレングリコール修飾インターフェロン組成物およびその使用方法 |
| EP1668129B1 (en) * | 2003-08-29 | 2008-10-29 | Children's Medical Center Corporation | Anti-angiogenic peptides from the n-terminus of endostatin |
| US7524811B2 (en) * | 2003-08-29 | 2009-04-28 | Children's Medical Center Corporation | Anti-angiogenic peptides from the N-terminus of endostatin |
| ATE555133T1 (de) | 2003-11-13 | 2012-05-15 | Hanmi Holdings Co Ltd | Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung |
| JP2008504008A (ja) | 2003-12-31 | 2008-02-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質 |
| CN100355784C (zh) | 2004-02-12 | 2007-12-19 | 江苏恒瑞医药股份有限公司 | 聚乙二醇修饰α－干扰素1b的制备方法 |
| JP2005245269A (ja) | 2004-03-03 | 2005-09-15 | Nipro Corp | 血清アルブミン多量体を含む遺伝子組換え型蛋白質 |
| WO2005111072A2 (en) | 2004-04-29 | 2005-11-24 | The Trustees Of Columbia University In The City Of New York | Notch-based fusion proteins and uses thereof |
| CN1311867C (zh) | 2004-09-27 | 2007-04-25 | 侯新朴 | 一种用于鼻腔给药的神经生长因子制剂 |
| CN1891717A (zh) * | 2005-07-08 | 2007-01-10 | 南京大学 | 内皮抑素的化学修饰方法及其应用 |
-
2006
- 2006-01-20 CN CNB2006100112479A patent/CN100475270C/zh not_active Expired - Lifetime
-
2007
- 2007-01-19 EP EP07702136.8A patent/EP1985302B1/en active Active
- 2007-01-19 CA CA2637698A patent/CA2637698C/en active Active
- 2007-01-19 WO PCT/CN2007/000204 patent/WO2007082483A1/zh not_active Ceased
- 2007-01-19 CN CN200780010122.7A patent/CN101405019B/zh active Active
- 2007-01-19 AU AU2007207268A patent/AU2007207268B2/en not_active Ceased
- 2007-01-19 US US12/161,477 patent/US20100285103A1/en not_active Abandoned
- 2007-01-19 JP JP2008550619A patent/JP5687823B2/ja not_active Expired - Fee Related
- 2007-01-19 CN CN201410160386.2A patent/CN104043107B/zh active Active
-
2008
- 2008-07-24 NO NO20083287A patent/NO20083287L/no not_active Application Discontinuation
-
2013
- 2013-02-26 JP JP2013036487A patent/JP2013163674A/ja active Pending
-
2018
- 2018-07-02 US US16/025,315 patent/US20180360922A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013163674A5 (https=) | ||
| WO2007082483B1 (en) | Medicament for treatment of tumor and the use thereof | |
| JP7161044B2 (ja) | 線維症における線維芽細胞活性化タンパク質（ｆａｐ）を標的とする撮像法および治療法 | |
| JP4514455B2 (ja) | Ｔｎｐ−４７０ポリマー複合体及びその使用 | |
| ES2744225T3 (es) | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos | |
| EP2063905B1 (en) | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates | |
| EP2113517B1 (en) | Conjugates comprising angiostatin and its fragments, methods for preparing the conjugates thereof | |
| JP2005500997A (ja) | トリメチルロック型テトラパルテートプロドラッグ | |
| US10413614B2 (en) | Conjugates for protection from nephrotoxic active substances | |
| CN105188728A (zh) | 用于肾靶向的肽和肽-活性物质-缀合物 | |
| CA2867611A1 (en) | Polymeric conjugates of c1-inhibitors | |
| US20200108143A1 (en) | Multi-drug delivery system and uses thereof | |
| CN114364402A (zh) | 用于治疗癌症的阿片类生长因子受体(ogfr)拮抗剂，特别是纳洛酮和/或纳曲酮 | |
| ES2742179T3 (es) | Composiciones farmacéuticas que comprenden agonistas del receptor de orexina-1 OX1R para el tratamiento de enfermedades inflamatorias del intestino | |
| WO2018086603A1 (zh) | 聚乙二醇化血管内皮抑制素类似物及其应用 | |
| US20220143203A1 (en) | Novel biomolecule conjugates and uses therefor | |
| WO2011083845A1 (ja) | 腫瘍部位に対する標的化剤 | |
| US20230173083A1 (en) | Albumin-binding prodrug for preventing or treating cancer and pharmaceutical composition including the same | |
| JP2016530221A (ja) | 生物学的活性成分の経口送達のための医薬製剤及び方法 | |
| WO2021219940A1 (en) | Homing peptide-guided decorin conjugates for use in treating epidermolysis bullosa | |
| JP6112009B2 (ja) | 体腔液貯留抑制剤 | |
| JP5961957B2 (ja) | 抗癌剤 | |
| CN101596320A (zh) | 一种治疗肿瘤的药物及其应用 |